Updates are available Correction dated 2020-03-25

Article History

Received: 28 September 2019

Accepted: 22 January 2020

First Online: 8 February 2020

Change Date: 25 March 2020

Change Type: Correction

Change Details: In the original publication of the article the author has found few incorrect values in the Table 1.

Compliance with ethical standards

:

: HMB: Consultancy: Endocyte, Celgene, Tracon, Guradant360; Honoraria: Bayer, SirTex. MM: Advisory board and consultancy: Blueprint Medicines, Immunocore, Amgen, Trieza, Array Biopharma, BionTech. WE: Consultancy and stock ownership: Inteliquet. DS: Advisory board: Sanofi, Genzyme; Consultancy: Harpoon Therapeutics; Research funding: Nectar, Celgene, Amgen, Pfizer, BMS, Leap, Corvus; Speaker’s bureau: Celgene, Genetech. MS: Advisory board: Celgene; Consultancy: Celgene, Abbvie, Astex, Karyopharm; Research support: Astex, Incyte, Sunesis, Takada, TG Therapeutics; Stock ownership: Karyopharm. SI: Research support: Celgene. JA, MA: Nothing to disclose. CLB, BS, EL, and KTT: Employment and stock ownership: Celgene. TH: Advisory board and honorarium: Genentech, Cardinal Health, Pfizer, Surface Oncology, Exelixis, Ipsen; Research funding: Novartis.

: This phase I, open-label, multicenter, randomized, crossover study was conducted in accordance with Good Clinical Practice, and adheres to the International Conference on Harmonization Guideline E6 and ethical principles outlined in the Declaration of Helsinki. The study received approval from relevant independent review boards or ethics committees before commencement. All patients provided written informed consent. This study is registered at ClinicalTrials.gov (NCT01519011).